---
title: "Everest Medicines Pays RMB200 Million Deposit for Potential Asia-Pacific Chronic Disease Portfolio Acquisition"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279444383.md"
description: "Everest Medicines Ltd. has signed a letter of intent to potentially acquire Hasten Biopharmaceuticals (SG) Pte. Ltd., which holds rights to 14 chronic disease products in the Asia-Pacific region. The company will pay a refundable RMB200 million deposit and gain six months of exclusivity for negotiations. This move aims to expand Everest's chronic disease portfolio. The current analyst rating for Everest Medicines (HK:1952) is a Hold with a price target of HK$36.00."
datetime: "2026-03-17T13:41:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279444383.md)
  - [en](https://longbridge.com/en/news/279444383.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279444383.md)
---

# Everest Medicines Pays RMB200 Million Deposit for Potential Asia-Pacific Chronic Disease Portfolio Acquisition

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Everest Medicines Ltd. ( (HK:1952) ) has provided an update.

Everest Medicines has signed a letter of intent with Hasten Biopharmaceuticals (Asia) Limited to potentially acquire the entire equity interest in Hasten Biopharmaceuticals (SG) Pte. Ltd., which holds commercial rights to 14 branded chronic disease products across multiple Asia-Pacific markets. Under the agreement, Everest will pay a refundable RMB200 million deposit funded from internal resources, gains six months of exclusivity to negotiate a definitive acquisition deal, and will conduct full due diligence on the target, positioning the company to expand its pan-Asia chronic disease portfolio and commercialization platform if the transaction proceeds.

The most recent analyst rating on (HK:1952) stock is a Hold with a HK$36.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.

**More about Everest Medicines Ltd.**

Everest Medicines Limited is a biopharmaceutical company that develops, manufactures and commercializes transformative pharmaceutical products and vaccines targeting critical unmet medical needs in Asian markets. The group focuses on acquiring and building Asia-Pacific pharmaceutical businesses with good prospects and stable returns, particularly in chronic disease segments across the region.

**Average Trading Volume:** 3,242,411

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$12.89B

For an in-depth examination of 1952 stock, go to TipRanks’ Overview page.

### Related Stocks

- [01952.HK](https://longbridge.com/en/quote/01952.HK.md)

## Related News & Research

- [Everest Medicines Directors and Major Shareholder Increase Stake, Signaling Confidence](https://longbridge.com/en/news/269638666.md)
- [Invitation to the Presentation of Cantargia's Interim Report for Q1 2026](https://longbridge.com/en/news/285339581.md)
- [11:21 ETWelltory Marks 10 Years, Launches Community Care for Chronic Conditions](https://longbridge.com/en/news/285231558.md)
- [SSY Group Wins Key China Drug Approvals, Expands Chronic and Pediatric Portfolio](https://longbridge.com/en/news/285308388.md)
- [MimiVax and Roswell Park open phase 2 trial of SurVaxM for metastatic neuroendocrine tumours](https://longbridge.com/en/news/285209353.md)